Pharma Journalist -

A pivotal Phase 3 trial evaluating Dupixent (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first…
Read More...

Stoke Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product candidate, STK-001, an investigational new…
Read More...

GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire,…
Read More...

Bayer and LANXESS sell their stakes in the chemical park operator Currenta to funds managed by Macquarie Infrastructure and Real Assets (MIRA), the world's largest infrastructure…
Read More...

Roche announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS). The combination of Tecentriq (atezolizumab)…
Read More...

Eli Lilly and Company announced that Emgality (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of…
Read More...

HCL Technologies (HCL), a leading global technology company and a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences announced a collaboration to help…
Read More...

Neuropore Therapies, Inc. announced that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were…
Read More...

Foamix Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in…
Read More...

Sosei Group Corporation announces that it has entered into a strategic multi-target partnership with Takeda Pharmaceutical Company Limited, to discover, develop and commercialize novel…
Read More...